(PharmaNewsWire.Com, July 26, 2017 ) According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)-Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha) . This receptor activates NF-kappaB mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS) .
The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase III Phase II Phase I Preclinical and Discovery stages are 1 2 1 2 and 2 respectively. Similarly the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules respectively. Report covers products from therapy areas Dermatology Immunology Gastrointestinal Central Nervous System Infectious Disease Oncology Ophthalmology and Respiratory which include indications Atopic Dermatitis Rheumatoid Arthritis Actinic (Solar) Keratosis Acute Lung Injury Acute Respiratory Distress Syndrome Crohn's Disease (Regional Enteritis) Genital Warts (Condylomata Acuminata) Inflammation Inflammatory Bowel Disease Melanoma Multiple Sclerosis Posterior Uveitis Psoriasis Soft Tissue Sarcoma and Warts.
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles Alvotech Iceland Eli Lilly and Company Eyevensys SAS G&E Herbal Biotechnology Co Ltd GlaxoSmithKline Plc Inflamalps SA Polaris Pharmaceuticals Inc
List of Tables Number of Products under Development by Stage of Development H2 2017 Number of Products under Development by Therapy Areas H2 2017 Number of Products under Development by Indication H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Number of Products under Investigation by Universities/Institutes H2 2017 Products under Investigation by Universities/Institutes H2 2017 Number of Products by Stage and Mechanism of Actions H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Pipeline by Alvotech Iceland H2 2017 Pipeline by Eli Lilly and Company H2 2017 Pipeline by Eyevensys SAS H2 2017 Pipeline by G&E Herbal Biotechnology Co Ltd H2 2017 Pipeline by GlaxoSmithKline Plc H2 2017 Pipeline by Inflamalps SA H2 2017 Pipeline by Polaris Pharmaceuticals Inc H2 2017 Dormant Products H2 2017 Dormant Products H2 2017 (Contd..1) H2 2017 Discontinued Products H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
